An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4011-4025

  Snijders, Antoine M ^a   Langley, Sasha ^a   Mao, Jian Hua ^a   Bhatnagar, Sandhya ^a   Bjornstad, Kathleen A ^a   Rosen, Chris J ^a   Lo, Alvin ^a   Huang, Yurong ^a   Blakely, Eleanor A ^a   Karpen, Gary H ^a   Bissell, Mina J ^a   Wyrobek, Andrew J ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Breast cancer; Estrous cycle; Genetic susceptibility; Immunity; Low dose ionizing radiation (LDIR); Mammary gland; RNA sequencing; Type 1 interferon

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; EOTAXIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 12; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DIESTRUS; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; ESTRUS; ESTRUS CYCLE; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IONIZING RADIATION; IRF3 GENE; IRF5 GENE; IRF7 GENE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; OVARIECTOMY; PPARA GENE; PPARG GENE; PROESTRUS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RNA SEQUENCE; SOD1 GENE; SOD2 GENE; SOD3 GENE; SREBF1 GENE; SREBF2 GENE; SURVIVAL PREDICTION; TRANSCRIPTION REGULATION; TYPE 1 INTERFERON GENE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; METASTASIS;

ANIMALS; DISEASE-FREE SURVIVAL; ESTROUS CYCLE; FEMALE; HUMANS; INTERFERONS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; RNA, MESSENGER;

EID: 84905109684     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2148     Document Type: Article

References (72)

1. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA and Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009; 27(22):3620-3626.
2. Hortobagyi GN. The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years? J Natl Cancer Inst. 2002; 94(9):641-643.
3. Senie RT and Tenser SM. The timing of breast cancer surgery during the menstrual cycle. Oncology (Williston Park). 1997; 11(10):1509-1517; discussion 1518-1522, 1524.
4. Randal J. Does the timing of breast cancer surgery affect survival? J Natl Cancer Inst. 1997; 89(7):473-477.
5. Hrushesky WJ. Menstrual cycle timing of breast cancer resection: prospective study is overdue. J Natl Cancer Inst. 1995; 87(2):143-144.
6. Larsen NS. Optimal timing of breast cancer surgery: findings revive debate. J Natl Cancer Inst. 1993; 85(8):605-607.
7. Hrushesky WJ, Bluming AZ and Gruber SA. Menstrual influence on surgical cure of breast cancer. Lancet. 1990; 335(8695):984.
8. Senie RT, Rosen PP, Rhodes P and Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med. 1991; 115(5):337-342.
9. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD and Fentiman IS. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 1991; 337(8752):1261-1264.
10. Kucuk AI and Atalay C. The Relationship between Surgery and Phase of the Menstrual Cycle Affects Survival in Breast Cancer. J Breast Cancer. 2012; 15(4):434-440.
11. Hagen AA and Hrushesky WJ. Menstrual timing of breast cancer surgery. Am J Surg. 1998; 175(3):245-261.
12. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R and et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet. 1994; 343(8912):1545-1547.
13. Mohr PE, Wang DY, Gregory WM, Richards MA and Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996; 73(12):1552-1555.
14. Badwe RA, Wang DY, Gregory WM, Fentiman IS, Chaudary MA, Smith P, Richards MA and Rubens RD. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994; 30A(4):445-448.
15. Thorpe H, Brown SR, Sainsbury JR, Perren TJ, Hiley V, Dowsett M, Nejim A and Brown JM. Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study. Br J Cancer. 2008; 98(1):39-44.
16. Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J and Maudelonde T. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer. 2001; 91(10):1854-1861.
17. Kroman N, Hojgaard A, Andersen KW, Graversen HP, Afzelius P, Lokdam A, Juul C, Hoffmann J, Bentzon N and Mouridsen HT. Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group. Eur J Surg Oncol. 1994; 20(4):430-435.
18. Ratajczak HV, Sothern RB and Hrushesky WJ. Estrous influence on surgical cure of a mouse breast cancer. J Exp Med. 1988; 168(1):73-83.
19. Vantyghem SA, Postenka CO and Chambers AF. Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res. 2003; 63(16):4763-4765.
20. Inano H, Ishii-Ohba H, Suzuki K and Yamanouchi H. Influence of the estrous cycle at gamma-ray exposure on radiation-induced mammary tumorigenesis in virgin rats. Int J Cancer. 1992; 52(3):414-417.
21. Ratko TA and Beattie CW. Estrous cycle modification of rat mammary tumor induction by a single dose of N-methyl-N-nitrosourea. Cancer Res. 1985; 45(7):3042-3047.
22. Fata JE, Chaudhary V and Khokha R. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod. 2001; 65(3):680-688.
23. Schedin P, Mitrenga T and Kaeck M. Estrous cycle regulation of mammary epithelial cell proliferation, differentiation, and death in the Sprague-Dawley rat: a model for investigating the role of estrous cycling in mammary carcinogenesis. J Mammary Gland Biol Neoplasia. 2000; 5(2):211-225.
24. Chua AC, Hodson LJ, Moldenhauer LM, Robertson SA and Ingman WV. Dual roles for macrophages in ovarian cycle-associated development and remodelling of the mammary gland epithelium. Development. 2010; 137(24):4229-4238.
25. Slaney CY, Rautela J and Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 2013; 73(19):5852-5857.
26. Hrushesky WJ, Gruber SA, Sothern RB, Hoffman RA, Lakatua D, Carlson A, Cerra F and Simmons RL. Natural killer cell activity: age, estrous-and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst. 1988; 80(15):1232-1237.
27. Trowell OA. The sensitivity of lymphocytes to ionising radiation. J Pathol Bacteriol. 1952; 64(4):687-704.
28. Hancock SL, Tucker MA and Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993; 85(1):25-31.
29. Boice JD, Jr., Harvey EB, Blettner M, Stovall M and Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992; 326(12):781-785.
30. Land CE, Boice JD, Jr., Shore RE, Norman JE and Tokunaga M. Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women. J Natl Cancer Inst. 1980; 65(2):353-376.
31. Shore RE, Hempelmann LH, Kowaluk E, Mansur PS, Pasternack BS, Albert RE and Haughie GE. Breast neoplasms in women treated with x-rays for acute postpartum mastitis. J Natl Cancer Inst. 1977; 59(3):813-822.
32. El-Saghire H, Michaux A, Thierens H and Baatout S. Low doses of ionizing radiation induce immune-stimulatory responses in isolated human primary monocytes. Int J Mol Med. 2013; 32(6):1407-1414.
33. Kataoka T. Study of antioxidative effects and anti-inflammatory effects in mice due to low-dose X-irradiation or radon inhalation. J Radiat Res. 2013; 54(4):587-596.
34. Saroha S, Uzzo RG, Plimack ER, Ruth K and Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013; 189(2):454-461.
35. Fumagalli LA, Vinke J, HoffW, Ypma E, Brivio F and Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother. 2003; 26(5):394-402.
36. Laloraya M, Kumar GP and Laloraya MM. Changes in the superoxide radical and superoxide dismutase levels in the uterus of Rattus norvegicus during the estrous cycle and a possible role for superoxide radical in uterine oedema and cell proliferation at proestrus. Biochem Cell Biol. 1991; 69(4):313-316.
37. Kasapovic J, Pajovic SB, Pejic S and Martinovic JV. Effects of estradiol benzoate and progesterone on superoxide dismutase activity in the thymus of rats. Physiol Res. 2001; 50(1):97-103.
38. Laloraya M, Pradeep KG and Laloraya MM. Changes in the levels of superoxide anion radical and superoxide dismutase during the estrous cycle of Rattus norvegicus and induction of superoxide dismutase in rat ovary by lutropin. Biochem Biophys Res Commun. 1988; 157(1):146-153.
39. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R and Hertzog PJ. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013; 41(Database issue):D1040-1046.
40. Rudolph MC, McManaman JL, Phang T, Russell T, Kominsky DJ, Serkova NJ, Stein T, Anderson SM and Neville MC. Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine. Physiol Genomics. 2007; 28(3):323-336.
41. Barber MC, Clegg RA, Travers MT and Vernon RG. Lipid metabolism in the lactating mammary gland. Biochim Biophys Acta. 1997; 1347(2-3):101-126.
42. Ivashkiv LB and Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014; 14(1):36-49.
43. Lee MS, Kim B, Oh GT and Kim YJ. OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat Immunol. 2013; 14(4):346-355.
44. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N and Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005; 434(7034):772-777.
45. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Moller A, Smyth MJ, Anderson RL, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18(8):1224-1231.
46. Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, Mathieson T, Hancock BA, Baptiste D, Atale R, Hickenbotham M, Zhu J, Glasscock J, Storniolo AM, Zheng F, Doerge R, et al. Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Res. 2014; 16(2):R26.
47. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA, Schjenken JE, Parker B, Gargett CE, Nguyen HP, Carr DJ, Hansbro PM, et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science. 2013; 339(6123):1088-1092.
48. Wen DX, Xu YF, Mais DE, Goldman ME and McDonnell DP. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol. 1994; 14(12):8356-8364.
49. Cato AC and Ponta H. Different regions of the estrogen receptor are required for synergistic action with the glucocorticoid and progesterone receptors. Mol Cell Biol. 1989; 9(12):5324-5330.
50. Snijders AM, Marchetti F, Bhatnagar S, Duru N, Han J, Hu Z, Mao JH, Gray JW and Wyrobek AJ. Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS One. 2012; 7(10):e45394.
51. Xu Y, Turner HC, Garty G and Brenner D. A Rapid, Quantitative Method to Characterize The Human Lymphocyte Concentration for Automated High-Throughput Radiation Biodosimetry. Biomed Eng Res. 2013; 2(1):16-19.
52. Blakely WF, Madrid JP and Sandgren DJ. Biodosimetry medical recording-use of the Biodosimetry Assessment Tool. Health Phys. 2010; 99 Suppl 5:S184-191.
53. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M and Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009; 125(6):1276-1284.
54. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV and Schillaci R. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res. 2008; 314(3):509-529.
55. Gouon-Evans V and Pollard JW. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology. 2001; 142(10):4515-4521.
56. Burke F. Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol Ther. 1999; 5(1):51-61.
57. Golab J and Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Int J Mol Med. 1999; 3(5):537-544.
58. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J and Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996; 7(16):1995-2002.
59. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ and Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-907.
60. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T and Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine. 2003; 24(3):81-90.
61. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med. 1998; 188(3):589-596.
62. Li S, Xia X, Mellieon FM, Liu J and Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther. 2004; 9(3):347-354.
63. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome biology. 2013; 14(4):R36.
64. Anders S, Pyl PT and Huber W. HTseq - A Python framework to work with high-throughput sequencing data. bioRxiv. 2014.
65. Loureiro JÉ, Rodriguez E, Dole≈ΩEl J and Santos CáÉ. Comparison of Four Nuclear Isolation Buffers for Plant DNA Flow Cytometry. Annals of Botany. 2006; 98(3):679-689.
66. Li J and Tibshirani R. Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Statistical methods in medical research. 2013; 22(5):519-536.
67. Anders S and Huber W. Differential expression analysis for sequence count data. Genome biology. 2010; 11(10):R106.
68. Li Q, Brown JB, Huang H and Bickel PJ. Measuring reproducibility of high-throughput experiments. Ann Appl Stat. 2011; 5(3):1699-2264.
69. Team RC. (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. R Foundation for Statistical Computing, Vienna, Asutria.
70. Chen H. VennDiagram: Generate high-resolution Venn and Euler plots. 2013.
71. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T, Maechler M, Magnusson A, Moeller S, Schwartz M and Venables B. gplots: Various R programming tools for plotting data. 2014.
72. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007; 25(10):1239-1246.